Pancreatic cancer is one of the leading causes for cancer-related deaths in the United
States. Majority of patients present with unresectable or metastatic disease. For those that …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Survival data for pancreatic cancer are usually based on actuarial calculations and actual
long-term survival rates are rarely reported. Here we use population-level data from the …

Objective: To describe accurately the pattern, timing, and predictors of disease recurrence
after a potentially curative resection for pancreatic ductal adenocarcinoma (PDAC) …

Background Exosomes arise from viable cancer cells and may reflect a different biology than
circulating cell-free DNA (cfDNA) shed from dying tissues. We compare exosome-derived …

Purpose To provide evidence-based recommendations to oncologists and others on
potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO …

Substantial progress has been made in our understanding of the biology of pancreatic
cancer, and advances in patients' management have also taken place. Evidence is …

Deaths from pancreatic ductal adenocarcinoma, also known as pancreatic cancer, rank
fourth among cancer-related deaths in the United States, yet the causes of pancreatic cancer …

Pancreatic cancer is almost invariably associated with mutations in the KRAS gene, most
commonly KRASG12D, that result in a dominant-active form of the KRAS GTPase. However …

Background Initial recurrence mapping of resected pancreatic ductal adenocarcinoma
(PDAC) could help in stratifying patient subpopulations for optimal postoperative follow-up …